Although the mere presence of pre-existing systemic anti-TERT CD4 T cells was not sufficient to predict survival in NSCLC patients [105], greater baseline values correlated with stronger protection, both in metastatic and localized NSCLC after chemotherapy (median OS of 17 vs. 9 months in anti-TERT Th1high vs anti-TERT Th1low, p = 0.023) [110]. This evidence concerns the gene TERT and non-small cell lung carcinoma.